Donath F, Quispe S, Diefenbach K, Maurer A, Fietze I, Roots I
Institute of Clinical Pharmacology, Charité University Medical Center, Humboldt University of Berlin, Germany.
Pharmacopsychiatry. 2000 Mar;33(2):47-53. doi: 10.1055/s-2000-7972.
A carefully designed study assessed the short-term (single dose) and long-term (14 days with multiple dosage) effects of a valerian extract on both objective and subjective sleep parameters. The investigation was performed as a randomised, double-blind, placebo-controlled, cross-over study. Sixteen patients (4 male, 12 female) with previously established psychophysiological insomnia (ICSD-code 1.A.1.), and with a median age of 49 (range: 22 to 55), were included in the study. The main inclusion criteria were reported primary insomnia according to ICSD criteria, which was confirmed by polysomnographic recording, and the absence of acute diseases. During the study, the patients underwent 8 polysomnographic recordings: i.e., 2 recordings (baseline and study night) at each time point at which the short and long-term effects of placebo and valerian were tested. The target variable of the study was sleep efficiency. Other parameters describing objective sleep structure were the usual features of sleep-stage analysis, based on the rules of Rechtschaffen and Kales (1968), and the arousal index (scored according to ASDA criteria, 1992) as a sleep microstructure parameter. Subjective parameters such as sleep quality, morning feeling, daytime performance, subjectively perceived duration of sleep latency, and sleep period time were assessed by means of questionnaires. After a single dose of valerian, no effects on sleep structure and subjective sleep assessment were observed. After multiple-dose treatment, sleep efficiency showed a significant increase for both the placebo and the valerian condition in comparison with baseline polysomnography. We confirmed significant differences between valerian and placebo for parameters describing slow-wave sleep. In comparison with the placebo, slow-wave sleep latency was reduced after administration of valerian (21.3 vs. 13.5 min respectively, p<0.05). The SWS percentage of time in bed (TIB) was increased after long-term valerian treatment, in comparison to baseline (9.8 vs. 8.1% respectively, p<0.05). At the same time point, a tendency for shorter subjective sleep latency, as well as a higher correlation coefficient between subjective and objective sleep latencies, were observed under valerian treatment. Other improvements in sleep structure - such as an increase in REM percentage and a decrease in NREM1 percentage - took place simultaneously under placebo and valerian treatment. A remarkable finding of the study was the extremely low number of adverse events during the valerian treatment periods (3 vs. 18 in the placebo period). In conclusion, treatment with a herbal extract of radix valerianae demonstrated positive effects on sleep structure and sleep perception of insomnia patients, and can therefore be recommended for the treatment of patients with mild psychophysiological insomnia.
一项精心设计的研究评估了缬草提取物对客观和主观睡眠参数的短期(单剂量)和长期(14天多剂量)影响。该研究采用随机、双盲、安慰剂对照、交叉试验设计。16例患者(4例男性,12例女性)被纳入研究,他们先前已确诊为心理生理性失眠(ICSD编码1.A.1.),中位年龄49岁(范围:22至55岁)。主要纳入标准为根据ICSD标准报告的原发性失眠,经多导睡眠图记录确认,且无急性疾病。在研究期间,患者接受了8次多导睡眠图记录:即在测试安慰剂和缬草短期及长期作用的每个时间点各进行2次记录(基线和研究夜)。该研究的目标变量是睡眠效率。描述客观睡眠结构的其他参数是基于 Rechtschaffen 和 Kales(1968年)规则的睡眠阶段分析的常见特征,以及作为睡眠微观结构参数的觉醒指数(根据1992年ASDA标准评分)。通过问卷评估主观参数,如睡眠质量、早晨感觉、白天表现、主观感知的睡眠潜伏期持续时间和睡眠时间。单剂量服用缬草后,未观察到对睡眠结构和主观睡眠评估的影响。多剂量治疗后,与基线多导睡眠图相比,安慰剂组和缬草组的睡眠效率均显著提高。我们证实了缬草和安慰剂在描述慢波睡眠的参数上存在显著差异。与安慰剂相比,服用缬草后慢波睡眠潜伏期缩短(分别为21.3分钟和13.5分钟,p<0.05)。长期服用缬草后,卧床时间(TIB)中的慢波睡眠百分比相对于基线有所增加(分别为9.8%和8.1%,p<0.05)。在同一时间点,缬草治疗组观察到主观睡眠潜伏期有缩短的趋势,以及主观和客观睡眠潜伏期之间的相关系数更高。在安慰剂组和缬草组治疗期间,睡眠结构的其他改善同时出现,如快速眼动睡眠百分比增加和非快速眼动睡眠1期百分比降低。该研究的一个显著发现是缬草治疗期间不良事件的数量极低(3例,而安慰剂组为18例)。总之,缬草提取物治疗对失眠患者的睡眠结构和睡眠感知有积极影响,因此可推荐用于治疗轻度心理生理性失眠患者。